What is the appropriate treatment for anemia?

Treatment of Anemia

The appropriate treatment for anemia depends fundamentally on the underlying etiology, with iron deficiency anemia treated first-line with oral ferrous sulfate (324 mg daily or twice daily between meals), while anemia of chronic disease—particularly in cardiovascular patients—requires intravenous iron therapy as first-line treatment, and restrictive transfusion strategies (hemoglobin threshold 7-8 g/dL) should be used for severe symptomatic anemia. 1, 2, 3

Initial Diagnostic Classification

• Obtain a complete blood count with indices and peripheral blood smear to characterize anemia morphologically based on mean corpuscular volume (MCV) 1
• Assess iron parameters including serum ferritin, transferrin saturation (TSAT), serum iron to distinguish iron deficiency from anemia of chronic disease 1, 2
• Screen for occult blood loss with stool and urine testing 1
• In patients with inflammation, ferritin >100 μg/L with TSAT <20% indicates pure anemia of chronic disease, while ferritin 30-100 μg/L suggests mixed iron deficiency and anemia of chronic disease 2

Iron Deficiency Anemia Treatment

Oral iron is the first-line therapy for uncomplicated iron deficiency anemia:

• Administer ferrous sulfate 324 mg (65 mg elemental iron) daily or twice daily between meals 1
• Add ascorbic acid 250-500 mg twice daily to improve iron absorption 1, 3
• Continue treatment for 2-3 months after hemoglobin normalization to replenish iron stores 1
• Repeat hemoglobin measurement after 4 weeks of treatment 1

Intravenous iron is indicated when:

• Oral iron is not tolerated or malabsorption is present 1
• Rapid repletion is needed 1
• Active inflammation is present (as in inflammatory bowel disease or rheumatoid arthritis), since inflammation inhibits oral iron absorption through hepcidin-mediated mechanisms 2, 4

Anemia of Chronic Disease Management

For patients with cardiovascular disease and anemia of chronic disease, intravenous iron therapy is the recommended first-line treatment:

• The European Society of Cardiology provides a Class IIA recommendation for IV iron therapy in heart failure patients with reduced ejection fraction and iron deficiency 1, 4
• Administer ferric carboxymaltose 200 mg weekly until ferritin >500 ng/mL, then 200 mg monthly for maintenance 1, 4
• IV iron improves exercise capacity, NYHA functional class, and quality of life scores, with approximately 50% of patients reporting moderate-to-marked improvement versus 28% with placebo 1, 4
• IV iron works better than oral supplementation because it bypasses the hepcidin-mediated blockade of intestinal iron absorption 1, 4

Treatment algorithm for anemia of chronic disease:

• Intensify therapy for the underlying inflammatory condition as the primary approach 2
• Use intravenous iron as first-line treatment in patients with clinically active disease, hemoglobin <100 g/L, previous intolerance to oral iron, or those requiring erythropoiesis-stimulating agents 2
• Monitor hemoglobin weekly after initiating therapy until stable, then at least monthly 2
• Measure iron parameters every 3 months during therapy 2
• Re-treat with intravenous iron when ferritin drops below 100 μg/L or hemoglobin falls below 120 g/L (women) or 130 g/L (men) 2

Transfusion Therapy

Use a restrictive red blood cell transfusion strategy:

• Transfuse only when hemoglobin falls to 7-8 g/dL in hospitalized patients, particularly those with coronary heart disease 3, 1, 4
• Reserve transfusion for severe symptomatic anemia or when rapid correction is needed 1
• Liberal transfusion strategies provide no mortality or hospitalization benefit and may cause harm, including transfusion-related acute lung injury, worsening heart failure, and fever 3, 4

Erythropoiesis-Stimulating Agents (ESAs)

Avoid ESAs in patients with mild to moderate anemia and heart disease:

• The American College of Physicians provides a strong recommendation against ESAs in patients with mild to moderate anemia and congestive heart failure or coronary heart disease 3, 1
• ESAs provide no mortality or hospitalization benefit and may cause harm, including hypertension, venous thromboembolism, and increased cardiovascular events 3, 4
• ESAs should be used with caution and only when hemoglobin is consistently below 10 g/dL with significant symptoms attributable to anemia 2
• In chronic kidney disease, erythropoiesis-stimulating agents are recommended as the preferred first-line therapy over hypoxia-inducible factor prolyl hydroxylase inhibitors due to persisting concerns regarding cardiovascular safety 5

Special Considerations

Iron-Refractory Iron Deficiency Anemia (IRIDA):

• In patients with unexplained microcytic anemia with low TSAT and normal or reduced ferritin who do not respond to oral iron but partially respond to intravenous iron, consider IRIDA due to TMPRSS6 defect 3
• Initial treatment with oral iron or oral iron combined with ascorbic acid should be considered 3
• If initial treatment does not result in acceptable hemoglobin levels, treat with intravenous iron supplementation 3
• Monitor serum ferritin levels and preferably keep below 500 mg/L to avoid toxicity of iron overload, especially in children and adolescents 3

Chronic Kidney Disease:

• Follow GFR-based management protocols in chronic kidney disease patients 2, 6
• Supplemental iron is required in the majority of CKD patients during ESA therapy 2
• The KDIGO 2026 guideline emphasizes comprehensive evaluation at diagnosis to identify additional causes of anemia beyond erythropoietin insufficiency 6, 5

Active Malignancy:

• Avoid ESAs in patients with active malignancy due to potential for tumor progression 2

Common Pitfalls to Avoid

• Do not use oral iron in patients with active inflammatory conditions, as inflammation inhibits absorption through hepcidin-mediated mechanisms 2, 4
• Do not exceed ferritin levels of 500 mg/L during intravenous iron therapy to avoid iron overload toxicity 3
• Do not use liberal transfusion strategies (hemoglobin >8-10 g/dL) as they provide no benefit and may cause harm 3, 4
• Do not attribute anemia solely to chronic disease without evaluating for concomitant true iron deficiency, vitamin B12 and folate deficiency, chronic blood loss, and hemolysis 2